Prime Medicine Inc (NASDAQ: PRME) on Tuesday, soared 7.67% from the previous trading day, before settling in for the closing price of $1.50. Within the past 52 weeks, PRME’s price has moved between $1.11 and $7.07.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 23.33%. With a float of $51.71 million, this company’s outstanding shares have now reached $131.16 million.
The extent of productivity of a business whose workforce counts for 214 workers is very important to gauge. In terms of profitability, gross margin is 95.87%, operating margin of -496.2%, and the pretax margin is -485.69%.
Prime Medicine Inc (PRME) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Prime Medicine Inc is 60.62%, while institutional ownership is 28.66%. The most recent insider transaction that took place on Jun 16 ’25, was worth 31,196. In this transaction 10% Owner of this company bought 21,000 shares at a rate of $1.49, taking the stock ownership to the 20,198,945 shares. Before that another transaction happened on Jun 11 ’25, when Company’s 10% Owner bought 21,000 for $1.60, making the entire transaction worth $33,590. This insider now owns 20,177,945 shares in total.
Prime Medicine Inc (PRME) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 23.33% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.30% during the next five years compared to -124.13% drop over the previous five years of trading.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
Prime Medicine Inc (PRME) is currently performing well based on its current performance indicators. A quick ratio of 4.78 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 55.08.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.66, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach -1.00 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
The latest stats from [Prime Medicine Inc, PRME] show that its last 5-days average volume of 2.18 million was superior to 1.59 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 45.10%. Additionally, its Average True Range was 0.17.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 22.67%, which indicates a significant decrease from 65.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 116.00% in the past 14 days, which was lower than the 117.26% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4101, while its 200-day Moving Average is $2.6957. Now, the first resistance to watch is $1.7633. This is followed by the second major resistance level at $1.9067. The third major resistance level sits at $1.9833. If the price goes on to break the first support level at $1.5433, it is likely to go to the next support level at $1.4667. The third support level lies at $1.3233 if the price breaches the second support level.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
Market capitalization of the company is 212.04 million based on 131,294K outstanding shares. Right now, sales total 2,980 K and income totals -195,880 K. The company made 1,450 K in profit during its latest quarter, and -51,890 K in sales during its previous quarter.
